HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. TECENTRIQ (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2024 RECENT MAJOR CHANGES
Refer to the respective prescribing information for bevacizumab, paclitaxel, and carboplatin for recommended dosing information TECENTRIQ in combination with nab-paclitaxel and carboplatin. Induction phase followed by chemotherapy-free infusions with TECENTRIQ.
Full prescribing information for Tecentriq Hybreza will be posted on Drugs@FDA. The approval was made on Septem. The content in
Description. Atezolizumab (Tecentriq) is a programmed death-ligand 1 (PD Tecentriq Prescribing Information. South San Francisco, CA: Genentech, Inc
There was a recent update to the TECENTRIQ (atezolizumab) Prescribing Information that impacted the dosing regimens for certain indications.
when prescribing Tecentriq for urothelial carcinoma, SCLC, NSCLC and TNBC including immune-mediated For more information, please refer to Tecentriq
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECENTRIQ HYBREZA safely and effectively. See full prescribing information for TECENTRIQ HYBREZA. TECENTRIQ HYBREZATM (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use Initial U.S. Approval: 2024
TECENTRIQ 840 mg IV over 60 minutes, followed by 100 mg/m TECENTRIQ 1200 mg intravenously HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. TECENTRIQ (atezolizumab) injection, for intravenous use
TECENTRIQ (atezolizumab). Tecentriq Website Prescribing Information Access Solutions Quick Enroll My Patient Solutions Login
Comments
SHOULD BE:
Andy had literally simply RELAYED all the various information.